News | Cardiovascular Ultrasound | April 30, 2019

New Guideline Published for Evaluation of Valvular Regurgitation After Catheter-based Valve Interventions

Document outlines technical considerations and imaging techniques as catheter-based valve interventions continue to increase

New Guideline Published for Evaluation of Valvular Regurgitation After Catheter-based Valve Interventions

April 30, 2019 — A new document compiled by four cardiac imaging professional societies provides a resource to guide clinicians in best practices for assessing valvular regurgitation following catheter-based repair or replacement of a valve. The document, available in full here, supplements the previously published guideline Recommendations for Evaluation of Prosthetic Valves with Echocardiography and Doppler Ultrasound.

Valvular regurgitation is a prevalent cardiac disorder, in which one or more of the heart’s valves leak, often leading to extra burdens on the heart muscle and requiring treatment. Catheter-based interventions to treat valvular heart disease (VHD) have increased over the past few years with the advent of transcatheter aortic valve replacement (TAVR), edge-to-edge mitral valve repair, and other investigative devices to repair or replace diseased valves. Guidelines to assess the results of these interventions, however, are lacking.

ASE’s Chair of the writing group, William A. Zoghbi, M.D., MACC, FASE, of Houston Methodist DeBakey Heart & Vascular Center in Houston, Texas, commented, “This new guideline is timely, as cardiologists and valvular heart disease specialists need consensus on how to evaluate results of catheter-based valve repair or replacement — novel approaches that help many patients with valve disease.”

Echocardiography is essential in the evaluation of valvular regurgitation after percutaneous interventions and is the first-line tool for evaluation of procedural results. Its assessment, however, is more difficult than in native valvular regurgitation because of the multitude of procedures and hardware involved. This highlights the need for an integrative approach of all information gleaned from various parameters.   

The document outlines in detail the technical considerations and imaging techniques, as well as the value that 3-D echocardiography and cardiac magnetic resonance imaging can add to the diagnostic process. It delves into specific issues with each type of regurgitation, namely mitral regurgitation (MR), aortic regurgitation (AR), tricuspid regurgitation (TR) and pulmonary regurgitation (PR). The document includes nine useful tables summarizing techniques and advantages of each modality, as well as 23 figures to illustrate various concepts.

In conjunction with the publication of this guideline Zoghbi will conduct a live webinar, including a question and answer section in June 2019. The webinar will be available for free to all American Society of Echocardiography (ASE) members and open to all other clinicians for $25. Registration and all ASE-hosted guideline webinars are available on ASEUniversity.org.

The full guideline document is available on the Journal of American Society of Echocardiography (JASE) website.

For more information: www.asecho.org

Related Content

Videos | Computed Tomography (CT) | July 19, 2019
Quynh Truong, M.D., MPH, associate professor of radio
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
Mednax National Cardiac Centers of Excellence Program Highlighted at SCCT 2019
News | CT Angiography (CTA) | July 11, 2019
Mednax Inc. and Mednax Radiology Solutions announced that Chief Medical Officer Ricardo C. Cury, M.D., FSCCT, will...
360 Photos | Ultrasound Imaging | July 11, 2019
This 360 degree photo shows a basic, point-of-care cardiac echocardiogram being performed using a smartphone turned i
Insightec's Exablate Neuro Approved With GE Signa Premier MRI in U.S. and Europe
News | Focused Ultrasound Therapy | July 10, 2019
GE Healthcare and Insightec announced U.S. Food and Drug Administration (FDA) approval and CE mark for Insightec’s...
Achenbach to Receive Inaugural 2019 Stephan Achenbach Pioneer Award in Cardiovascular CT
News | Cardiac Imaging | July 10, 2019
The Society of Cardiovascular Computed Tomography (SCCT) will present Stephan Achenbach, M.D., FSCCT with the inaugural...
360 Photos | Ultrasound Imaging | July 09, 2019
A view of a mitral valve on a GE Healthcare Vivid E95 ...